Orchestra BioMed Holdings (OBIO) Gross Margin (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has 5 years of Gross Margin data on file, last reported at 70.91% in Q1 2026.

• On a quarterly basis, Gross Margin fell 2402.0% year-over-year to 70.91% in Q1 2026; TTM through Mar 2026 was 99.46%, a 687.0% increase from a year earlier, with the FY2025 full-year figure at 99.43%, up 717.0% from the prior year.
• Gross Margin for Q1 2026 stood at 70.91%, down from 99.84% in the prior quarter.
• Over the last five years, Gross Margin for OBIO reached as high as 99.84% in Q4 2025 and fell as low as 70.91% in Q1 2026.
• Historically, Gross Margin has averaged 90.98% across 5 years, with a median of 94.34% in 2024.
• Across the five-year window, Gross Margin surged 2276 bps in 2025 and sank 2402 bps in 2026, its largest moves.
• Year by year, Gross Margin stood at 95.19% in 2022, then decreased by 14 bps to 82.06% in 2023, then declined by 6 bps to 77.08% in 2024, then rose by 30 bps to 99.84% in 2025, then fell by 29 bps to 70.91% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 70.91% in Q1 2026, 99.84% in Q4 2025, and 94.31% in Q3 2025.